Tokyo Tape
Sign in
← PeptiDream

Half-year report · HY

4587.TEDINET S100YVU6
Period2026-01-01 → 2026-06-30
Filed2026-08-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥9.2bn2026-01-01 → 2026-06-30Cons.Revenue IFRS
Revenue¥18.5bn2025-01-01 → 2025-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥8.5bn2025-01-01 → 2025-06-30Cons.Revenue IFRS
Operating income−¥2.5bn2026-01-01 → 2026-06-30Cons.Operating profit loss IFRS
Operating income−¥2.6bn2025-01-01 → 2025-06-30Cons.Operating profit loss IFRS
Profit before tax−¥2.7bn2026-01-01 → 2026-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥5.3bn2025-01-01 → 2025-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥2.9bn2025-01-01 → 2025-06-30Cons.Profit loss before tax IFRS
Net income (owners)−¥2.0bn2026-01-01 → 2026-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥3.7bn2025-01-01 → 2025-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥2.1bn2025-01-01 → 2025-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income−¥2.0bn2026-01-01 → 2026-06-30Cons.Profit loss IFRS
Net income−¥3.7bn2025-01-01 → 2025-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥2.1bn2025-01-01 → 2025-06-30Cons.Profit loss IFRS
Total assets¥72.2bnat 2026-06-30Cons.Assets IFRS
Total assets¥77.0bnat 2025-12-31Cons.Assets IFRS
Total assets¥78.5bnat 2025-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥23.7bnat 2026-06-30Cons.Liabilities IFRS
Total liabilities¥25.5bnat 2025-12-31Cons.Liabilities IFRS
Net assets / equity¥48.6bnat 2026-06-30Cons.Equity IFRS
Net assets / equity¥51.5bnat 2025-12-31Cons.Equity IFRS
Net assets / equity¥53.7bnat 2025-06-30Cons.Equity IFRS
Net assets / equity¥56.8bnat 2024-12-31vCons.Equity IFRS
Equity (owners)¥48.6bnat 2026-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥51.5bnat 2025-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥53.7bnat 2025-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥23.6bnat 2026-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥28.7bnat 2025-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥33.3bnat 2025-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥48.1bnat 2024-12-31vCons.Cash and cash equivalents IFRS
Operating cash flow−¥1.8bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow−¥13.3bn2025-01-01 → 2025-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥11.0bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥614m2026-01-01 → 2026-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥2.1bn2025-01-01 → 2025-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥1.3bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥2.7bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥4.1bn2025-01-01 → 2025-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥2.5bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-15.512026-01-01 → 2026-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-28.992025-01-01 → 2025-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-16.42025-01-01 → 2025-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥-15.512026-01-01 → 2026-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-28.992025-01-01 → 2025-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-16.42025-01-01 → 2025-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio67.2%at 2026-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio66.9%at 2025-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio68.3%at 2025-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2026-01-01 → 2026-06-30−¥512m
Reconciling Itemsreconcilingrevenue intersegment2026-01-01 → 2026-06-30−¥512m
Drug Discovery And Development Businessreportable segmentrevenue2026-01-01 → 2026-06-30¥1.2bn
Drug Discovery And Development Businessreportable segmentrevenue external2026-01-01 → 2026-06-30¥1.2bn
Drug Discovery And Development Businessreportable segmentsegment profit2026-01-01 → 2026-06-30−¥2.7bn
Radiopharmaceuticals Businessreportable segmentrevenue2026-01-01 → 2026-06-30¥8.5bn
Radiopharmaceuticals Businessreportable segmentrevenue external2026-01-01 → 2026-06-30¥8.0bn
Radiopharmaceuticals Businessreportable segmentrevenue intersegment2026-01-01 → 2026-06-30¥512m
Radiopharmaceuticals Businessreportable segmentsegment profit2026-01-01 → 2026-06-30¥242m
—segment totalrevenue2026-01-01 → 2026-06-30¥9.7bn
—segment totalrevenue external2026-01-01 → 2026-06-30¥9.2bn
—segment totalrevenue intersegment2026-01-01 → 2026-06-30¥512m
—segment totalsegment profit2026-01-01 → 2026-06-30−¥2.5bn
Reconciling Itemsreconcilingrevenue2025-01-01 → 2025-06-30−¥453m
Reconciling Itemsreconcilingrevenue intersegment2025-01-01 → 2025-06-30−¥453m
Drug Discovery And Development Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥761m
Drug Discovery And Development Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥761m
Drug Discovery And Development Businessreportable segmentsegment profit2025-01-01 → 2025-06-30−¥3.0bn
Radiopharmaceuticals Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥8.2bn
Radiopharmaceuticals Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥7.8bn
Radiopharmaceuticals Businessreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥453m
Radiopharmaceuticals Businessreportable segmentsegment profit2025-01-01 → 2025-06-30¥436m
—segment totalrevenue2025-01-01 → 2025-06-30¥9.0bn
—segment totalrevenue external2025-01-01 → 2025-06-30¥8.5bn
—segment totalrevenue intersegment2025-01-01 → 2025-06-30¥453m
—segment totalsegment profit2025-01-01 → 2025-06-30−¥2.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 571
ItemContextValueUnit
Other non current liabilities ncl IFRSPrior1YearInstant660000JPY
Other non current liabilities ncl IFRSInterimInstant660000JPY
Non current labilities IFRSPrior1YearInstant2086382000JPY
Non current labilities IFRSInterimInstant15697570000JPY
Liabilities IFRSPrior1YearInstant25504924000JPY
Liabilities IFRSInterimInstant23670778000JPY
Share capital IFRSPrior1YearInstant3956738000JPY
Share capital IFRSInterimInstant3956738000JPY
Capital surplus IFRSPrior1YearInstant4653758000JPY
Capital surplus IFRSInterimInstant4504429000JPY
Treasury shares IFRSPrior1YearInstant-1897778000JPY
Treasury shares IFRSInterimInstant-2715872000JPY
Retained earnings IFRSPrior1YearInstant45586799000JPY
Retained earnings IFRSInterimInstant43587375000JPY
Other components of equity IFRSPrior1YearInstant-771254000JPY
Other components of equity IFRSInterimInstant-777523000JPY
Equity attributable to owners of parent IFRSPrior1YearInstant51528263000JPY
Equity attributable to owners of parent IFRSInterimInstant48555147000JPY
Equity IFRSPrior1YearInstant51528263000JPY
Equity IFRSInterimInstant48555147000JPY
Liabilities and equity IFRSPrior1YearInstant77033187000JPY
Liabilities and equity IFRSInterimInstant72225925000JPY
Revenue IFRSPrior1InterimDuration8543788000JPY
Revenue IFRSInterimDuration9226971000JPY
Cost of sales IFRSPrior1InterimDuration5378208000JPY
Cost of sales IFRSInterimDuration5258941000JPY
Gross profit IFRSPrior1InterimDuration3165579000JPY
Gross profit IFRSInterimDuration3968029000JPY
Selling general and administrative expenses IFRSPrior1InterimDuration3651641000JPY
Selling general and administrative expenses IFRSInterimDuration3838863000JPY
Research and development expenses IFRSPrior1InterimDuration2135722000JPY
Research and development expenses IFRSInterimDuration2642767000JPY
Other income IFRSPrior1InterimDuration1385000JPY
Other income IFRSInterimDuration906000JPY
Other expenses IFRSPrior1InterimDuration5444000JPY
Other expenses IFRSInterimDuration22087000JPY
Operating profit loss IFRSPrior1InterimDuration-2625842000JPY
Operating profit loss IFRSInterimDuration-2534782000JPY
Finance income IFRSPrior1InterimDuration162294000JPY
Finance income IFRSInterimDuration135053000JPY
Finance costs IFRSPrior1InterimDuration367059000JPY
Finance costs IFRSInterimDuration258737000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1InterimDuration-31905000JPY
Share of profit loss of investments accounted for using equity method IFRSInterimDuration-1323000JPY
Profit loss before tax IFRSPrior1InterimDuration-2862513000JPY
Profit loss before tax IFRSInterimDuration-2659790000JPY
Income tax expense IFRSPrior1InterimDuration-740023000JPY
Income tax expense IFRSInterimDuration-660365000JPY
Profit loss IFRSPrior1InterimDuration-2122490000JPY
Profit loss IFRSInterimDuration-1999424000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2025-12-31pass
balance sheet identityconsolidated 2026-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-06-30pass
statement vs summary · net income attributable to parentconsolidated 2026-01-01/2026-06-30pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2026-01-01/2026-06-30pass
statement vs summary · revenueconsolidated 2025-01-01/2025-06-30pass
statement vs summary · revenueconsolidated 2026-01-01/2026-06-30pass
statement vs summary · total assetsconsolidated 2025-12-31pass
statement vs summary · total assetsconsolidated 2026-06-30pass